Smoking Claims More Than 6,500 Lives, Costs Minnesota Over $9 Billion Annually
New report commissioned by Blue Cross and Blue Shield of Minnesota exposes the ramifications of smoking on health and the...
Disability
Introducing Elument: Trailblazing the Future of Mental Health and Wellness
NASHVILLE, TN / ACCESSWIRE / January 16, 2024 / Elument,a trailblazer in mental health & wellness services, is proud to...
Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication
-Phase 1b/2a clinical trial in acute ischemic stroke expected to initiate in 1H 2024- -Marks the first IND for Aruna’s...
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
TORONTO, ON / ACCESSWIRE / January 15, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ")...
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital
-- Brooks Rehabilitation Hospital adds a second site to the registrational program in stroke, and brings the total number of...
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
Initiation of REVEAL pediatric trial in the U.S. broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old...
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
MIAMI, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations;...
ReWalk Robotics CEO Issues Year-End 2023 Open Letter to Shareholders and Provides 2024 Commercial and Operational Priorities
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”...
American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event
This is the second CPT PLA code the American Medical Association (AMA) granted for the Company’s AI-powered coronary heart disease...
Anavex Life Sciences Provides an Update on Rett Syndrome Program
Anavex Announces Topline Results from Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome Validation from Real World Evidence (RWE)...
Equal Opportunity and Respect: Diversity, Inclusion and Belonging at Alkermes
Originally published in Alkermes September 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 27, 2023 / Our employees are...
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat...
Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
PHOENIX, AZ / ACCESSWIRE / December 20, 2023 / Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a biotechnology company has received...
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
Relationship leverages Quest's sequencing and specimen collection expertise with Scipher's precision medicine technologySECAUCUS, NJ and WALTHAM, MA / ACCESSWIRE /...
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
Journal of Nanobiotechnology publication describes results from the successful Phase 2 REPAIR clinical studies that measured changes in brain energy...
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a...
Theralase Release’s 3Q2023 Interim Financial Statements
TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...